- No file added yet -

INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance - PLSP

figure

posted on 2021-12-17, 12:23 authored by Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye Mun Tho, Xiuning Le, Julien Mazieres, How Soon Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl Maria Schumacher, Niki Karachaliou, Yi-Long Wu

Plain Language Summary